Nephrogenic systemic fibrosis;Nephrogene systemische fibrose

Medizinische Monatsschrift fur Pharmazeuten

Volumn 32, Issue 10, 2009, Pages 377-382

  Breitschaft, Astrid ^a   Stahlmann, Ralf ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GADOBENATE DIMEGLUMINE; GADOBUTROL; GADODIAMIDE; GADOFOSVESET; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE; GADOTERATE MEGLUMINE; GADOTERIDOL; GADOVERSETAMIDE; GADOXETIC ACID; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; TRANSFORMING GROWTH FACTOR BETA;

DRUG APPROVAL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG STRUCTURE; FOOD AND DRUG ADMINISTRATION; HEMODIALYSIS PATIENT; HUMAN; JOINT CONTRACTURE; KIDNEY FAILURE; MACROPHAGE; MAGNETIC RESONANCE ANGIOGRAPHY; NEPHROGENIC SYSTEMIC FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PLASMAPHERESIS; PUVA; REVIEW; RISK BENEFIT ANALYSIS; SCLEROMYXEDEMA;

CONTRAST MEDIA; FIBROSIS; GADOLINIUM; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY DISEASES; SKIN DISEASES;

EID: 70350339783     PISSN: 03429601     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. BfArM 2007. http://www.bfarm.de/Pharmakovigilanz/Risikoinformationen/aus 2007 (letzter Zugriff am 17.03.2009).
2. BfArM 2008. http://www.bfarm.de/Pharmakovigilanz/Risikoinformationen/aus 2008 (letzter Zugriff am 17.03.2009).
3. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med 2000;342:1350-1358 (Pubitemid 30408720)
4. Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994;331:1286-1292 (Pubitemid 24333194)
5. Broome DR, Girguis MS, Baron PW, Cottrell AC, et al. Gadodiamide- associated nephrogenic systemic fibrosis: why radiologists should be concerned. Am J Roentgenol 2007;188:586-592 (Pubitemid 46167763)
6. Bucala R. Fibrocytes: discovery of a circulating connective tissue cell progenitor. In: R. Bucala, Editor, Fibrocytes. New Insights into Tissue repair and Systemic Fibrosis, World Scientific, Hackensack (2007), pp. 1-18.
7. Cowper SE, Robin HS, Steinberg SM, Su LD, et al. Scleromyxoedema- like cutaneous disease in renal-dialysis patients. Lancet 2000;356:1000-1001
8. Cowper SE. Nephrogenic Fibrosing Dermopathy: The First Six Years. Curr Opin Rheumatol 2003;15:785-790
9. Cowper SE. Nephrogenic Fibrosing Dermopathy. http://www.icnfdr. org. 2001-2008 (letzter Zugriff am 17.03.2009).
10. Di Sabatino A, Jackson C, Pickard K, Buckley M, et al. Transforming growth factor-β signalling and matrix metalloproteinases in the mucosa overlying Crohns disease strictures. Gut 2009;58:777-789
11. Edward M, Quinn JA, Mukherjee S, Jensen MB, et al. Gadodiamide contrast agent 'activates' fibroblasts: a possible cause of nephrogenic systemic fibrosis. J Pathol 2008;214:584-593
12. Fachinformation Omniscan® 0,5 mmol/l Injektionslösung (Stand 12.10.2007).
13. Fachinformation Vasovist® 0,25 mmol/ml Injektionslösung (Stand 07/2008).
14. FDA 2007. http://www.fda.gov/cder/drug/advisory/gadolinium-agents- 20061222.htm (letzter Zugriff am 17.03.2009).
15. Goddard DS, Magee CC, Lazar AJF, Miller DM. Nephrogenic fibrosing dermopathy with recurrence after allograft failure. J Am Acad Dermatol 2007;56:S109-11.
16. Grobner T. Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006;21:1104-1108
17. Idée JM, Port M, Medina C, Lancelot E, et al. Possible involvement of gadolinium chelates in the pathophysiology of nephrogenic systemic fibrosis: a critical review. Toxicology 2008;248:77-88.
18. Jimenez SA, Artlett CM, Sandorfi N, Derk C, et al. Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor beta1 expression in affected skin. Arthritis Rheum 2004;50:2660-2666 (Pubitemid 39062729)
19. Kelly B, Petitt M, Sanchez R. Nephrogenic systemic fibrosis is associated with transforming growth factor beta and Smad without evidence of renin-angiotensin system involvement. J Am Acad Dermatol 2008;58:1025-1030 (Pubitemid 351657614)
20. Levine JM, Taylor RA, Elman LB, Bird SJ, et al. Involvement of skeletal muscle in dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy). Muscle Nerve 2004;30:569-577
21. Marckmann P, Skov L, Rossen K, Dupont A, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast- enhanced magnetic resonance imaging. J Am Soc Nephrol 2006;17: 2359-2362 (Pubitemid 44300951)
22. Marckmann P, Skov L, Rossen K, Heaf JG, Thomsen HS. Case-control study of gadodiamide-related nephrogenic systemic fibrosis. Nephrol Dial Transplant 2007;22:3174-3178 (Pubitemid 350202540)
23. Medicines and Healthcare products Regulatory Agency. http://www. mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safety- warningsandmessagesformedicines/CON2031543 (letzter Zugriff am 17.03.2009).
24. Mendoza FA, Artlett CM, Sandorfi N, Latinis K, et al. Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature. Semin Arthritis Rheum 2006;35:238-249 (Pubitemid 43185214)
25. Nunes I, Gleizes PE, Metz CN, Rifkin DB. Latent transforming growth factor-beta binding protein domains involved in activation and transglutaminase-dependent cross-linking of latent transforming growth factor- beta. J Cell Biol 1997;136:1151-1163 (Pubitemid 27131745)
26. Ortonne N, Lipsker D, Chantrel F, Boehm N, et al. Presence of CD45RO+ CD34+ cells with collagen synthesis activity in nephrogenic fibrosing dermopathy: a new pathogenic hypothesis. Br J Dermatol 2004;150:1050-1052 (Pubitemid 38903558)
27. Parsons AC, Yosipovitch G, Sheehan DJ, Sangüeza OP, et al. Transglutaminases: the missing link in nephrogenic systemic fibrosis. Am J Dermatopathol. 2007;29:433-436 (Pubitemid 47463850)
28. Perazella MA. Nephrogenic systemic fibrosis, kidney disease, and gadolinium: is there a link? Clin J Am Soc Nephrol 2007;2:200-202
29. Perazella MA. Current status of gadolinium toxicity in patients with kidney disease. Clin J Am Soc Nephrol 2009;4:461-469
30. Perez-Rodriguez J, Lai S, Ehst BD, Fine DM, Bluemke DA. Nephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessment-report of 33 cases. Radiology 2009;250:371-377
31. Quan TE, Cowper S, Wu SP, Bockenstedt LK, Bucala R. Circulating fibrocytes: Collagen-secreting cells of the peripheral blood. Int J Biochem Cell Biol 2004;36:598-606. (Pubitemid 38316817)
32. Quan TE, Cowper SE, Bucala R. The role of circulating fibrocytes in fibrosis. Curr Rheumatol Rep 2006;8:145-150
33. Reilly RF. Risk for nephrogenic systemic fibrosis with gadoteridol (ProHance) in patients who are on long-term hemodialysis. Clin J Am Soc Nephrol 2008;3:747-751
34. Sadowski EA, Bennett LK, Chan MR, Wentland AL, Garrett AL, Garrett RW, Djamali A. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 2007;243:148-157 (Pubitemid 46579705)
35. Signorini M, Bortolotti F, Poltronieri L, Bergamini CM. Human erythrocyte transglutaminase: purification and preliminary characterisation. Biol Chem Hoppe Seyler 1988;369:275-281 (Pubitemid 18114590)
36. Swaminathan S, Ahmed I, McCarthy JT, Albright RC, et al. Nephrogenic fibrosing dermopathy and high-dose erythropoietin therapy. Ann Intern Med 2006;145:234-235 (Pubitemid 46780577)
37. Ting WW, Stone MS, Madison KC, Kurtz K. Nephrogenic Fibrosing Dermopathy with Systemic Involvement. Archiv Dermatol 2003;139:903-906
38. Varani J, Dasilva M, Warner RL, O'Brien Deming M, Barron AG, et al. Effects of Gadolinium-Based Magnetic Resonance Imaging Contrast Agents on Human Skin in Organ Culture and Human Skin Fibroblasts. Invest Radiol 2009;44:74-81.
39. Wiginton CD, Kelly B, Oto A, Jesse M, et al. Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue. Am J Roentgenol 2008;190:1060-1068 (Pubitemid 351571526)